Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

NZ sharemarket closes lower, tech stocks buoyed by Oracle update
Markets Market Close

NZ sharemarket closes lower, tech stocks buoyed by Oracle update

The S&P/NZX 50 Index closed down 0.35% or 47.09 points.

Tom Raynel 11 Sep 2025
Average home insurance tops $2,000
Infrastructure Risky Business

Average home insurance tops $2,000

Insurance premiums in New Zealand have increased dramatically in recent years.

Michael Neilson 11 Sep 2025
How RFK Jnr's Medicare reform could aid this NZ firm
Markets

How RFK Jnr's Medicare reform could aid this NZ firm

'Wild west' conditions hampered its US push. They could be changing.